This means that they would not be appropriate for treating RAS-mutant cancers, however they could potentially be a future replacement for type I1⁄2 RAFi for the treatment of BRAF mutant cancers such as most melanoma and hairy-cell leukaemia without paradoxically inducing tumour formation. The gene discussed is BRAF; the disease is melanoma.